Investigator

Pierre Martin‐Hirsch

Lancashire Teaching Hospitals Nhs Foundation Trust

Research Interests

PMPierre Martin‐Hir…
Papers(3)
Treatment methods for…Diagnostic Accuracy o…Diagnostic performanc…
Collaborators(10)
Christina FotopoulouDow-Mu KohGary J. CookTara D. BarwickKatja N De PaepeMarc MiquelAslam SohaibAndrea G RockallNishat BharwaniRanjit Manchanda
Institutions(6)
Lancashire Teaching H…Imperial College Lond…Royal Marsden Hospita…King's College LondonInstitute Of Cancer R…Guy's and St Thomas' …

Papers

Treatment methods for cervical intraepithelial neoplasia in England: A cost‐effectiveness analysis

AbstractObjectiveTo compare the cost‐effectiveness of different treatments for cervical intraepithelial neoplasia (CIN).DesignA cost‐effectiveness analysis based on data available in the literature and expert opinion.SettingEngland.PopulationWomen treated for CIN.MethodsWe developed a decision‐analytic model to simulate the clinical course of 1000 women who received local treatment for CIN and were followed up for 10 years after treatment. In the model we considered surgical complications as well as oncological and reproductive outcomes over the 10‐year period. The costs calculated were those incurred by the National Health Service (NHS) of England.Main outcome measuresCost per one CIN2+ recurrence averted (oncological outcome); cost per one preterm birth averted (reproductive outcome); overall cost per one adverse oncological or reproductive outcome averted.ResultsFor young women of reproductive age, large loop excision of the transformation zone (LLETZ) was the most cost‐effective treatment overall at all willingness‐to‐pay thresholds. For postmenopausal women, LLETZ remained the most cost‐effective treatment up to a threshold of £31,500, but laser conisation became the most cost‐effective treatment above that threshold.ConclusionsLLETZ is the most cost‐effective treatment for both younger and older women. However, for older women, more radical excision with laser conisation could also be considered if the NHS is willing to spend more than £31,500 to avert one CIN2+ recurrence.

Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma

Abstract Purpose: Preoperative nodal staging is important for planning treatment in cervical cancer and endometrial cancer, but remains challenging. We compare nodal staging accuracy of 18F-ethyl-choline-(FEC)-PET/CT, 18F-fluoro-deoxy-glucose-(FDG)-PET/CT, and diffusion-weighted-MRI (DW-MRI) with conventional morphologic MRI. Experimental Design: A prospective, multicenter observational study of diagnostic accuracy for nodal metastases was undertaken in 5 gyne-oncology centers. FEC-PET/CT, FDG-PET/CT, and DW-MRI were compared with nodal size and morphology on MRI. Reference standard was strictly correlated nodal histology. Eligibility included operable cervical cancer stage ≥ 1B1 or endometrial cancer (grade 3 any stage with myometrial invasion or grade 1–2 stage ≥ II). Results: Among 162 consenting participants, 136 underwent study DW-MRI and FDG-PET/CT and 60 underwent FEC-PET/CT. In 118 patients, 267 nodal regions were strictly correlated at histology (nodal positivity rate, 25%). Sensitivity per patient (n = 118) for nodal size, morphology, DW-MRI, FDG- and FEC-PET/CT was 40%*, 53%, 53%, 63%*, and 67% for all cases (*, P = 0.016); 10%, 10%, 20%, 30%, and 25% in cervical cancer (n = 40); 65%, 75%, 70%, 80% and 88% in endometrial cancer (n = 78). FDG-PET/CT outperformed nodal size (P = 0.006) and size ratio (P = 0.04) for per-region sensitivity. False positive rates were all <10%. Conclusions: All imaging techniques had low sensitivity for detection of nodal metastases and cannot replace surgical nodal staging. The performance of FEC-PET/CT was not statistically different from other techniques that are more widely available. FDG-PET/CT had higher sensitivity than size in detecting nodal metastases. False positive rates were low across all methods. The low false positive rate demonstrated by FDG-PET/CT may be helpful in arbitration of challenging surgical planning decisions.

Diagnostic performance of quantitative measures from [18F]FDG PET/CT, [18F]FEC PET/CT, and DW-MRI in the detection of lymph node metastases in endometrial and cervical cancer: data from the MAPPING study

Abstract Purpose To evaluate the diagnostic performance of quantitative measures derived from [ 18 F]FDG PET/CT, [ 18 F]FEC PET/CT, and DW-MRI in the detection of lymph node metastases in endometrial and cervical cancer with comparison to standard visual PET analysis with histology as the reference standard. Methods Subanalysis of quantitative data from the prospective multicentre MAPPING study. Nodal and tumour SUV max from [ 18 F]FDG PET/CT and [ 18 F]FEC PET/CT and ADC mean from DW-MRI were documented. Nodal-to-tumour ratios (NTR) and SUV max -to-ADC mean ratio (STAR) were calculated. Optimal cut-offs of quantitative measures were compared to visual assessment on a regional basis using histopathology as the reference standard. Results Scans from 112 patients (36 cervical and 76 endometrial cancers; 340 nodal regions) were eligible for quantitative image analysis. Lower ADC mean on DW-MRI was observed in metastatic nodes for cervical cancer but not for endometrial cancer. Quantitative measures were significantly higher in malignant than benign nodal regions on [ 18 F]FDG PET/CT and [ 18 F]FEC PET/CT in endometrial cancer. SUV max cut-offs showed similar performance to visual assessment in the diagnosis of metastatic lymph nodes in endometrial cancer whilst ADC mean cut-offs showed significantly lower specificity than visual assessment. Interobserver agreement was excellent for SUV max measurements on both [ 18 F]FDG PET/CT and [ 18 F]FEC PET/CT, but poor for ADC mean on DW-MRI. Conclusion Quantitative measures from [ 18 F]FDG PET/CT, [ 18 F]FEC PET/CT, or DW-MRI did not outperform visual assessment in the detection of nodal metastases in endometrial cancer. Therefore, the implementation of these quantitative measures as standalone diagnostic tools in routine clinical practice is not recommended.

224Works
3Papers
21Collaborators
Uterine Cervical NeoplasmsEndometrial NeoplasmsNeoplasm Recurrence, LocalNeoplasm StagingOvarian Neoplasms
Links & IDs
0000-0002-0520-0066

Scopus: 57203223829